Tech Company Financing Transactions
Orakl Oncology Funding Round
Norrsken VC, Bpifrance and HCVC participated in a $34 million Series A funding round for Orakl Oncology. This venture round was announced on 11/12/2026.
Transaction Overview
Company Name
Announced On
11/12/2026
Transaction Type
Venture Equity
Amount
$34,000,000
Round
Series A
Investors
Proceeds Purpose
Orakl Oncology will use the $34 million funding to expand its proprietary cancer research dataset and AI research team, increase experimental data generation fivefold, and extend its AI-powered virtual cancer patient platform beyond colorectal and pancreatic cancers into lung and gastric cancers. The company also plans to establish teams in the United States and United Kingdom to support more than 10 pharmaceutical drug development programmes. Additionally, the funding will support the development of new capabilities to discover and validate drug targets using patient-derived tumour models, clinical data and AI, helping pharmaceutical companies predict cancer drug effectiveness before clinical trials and improve drug development outcomes.
Company Information
Company Status
Private & Independent
Industry
Artificial Intelligence
Mailing Address
63 rue Gabriel Peri
Le Kremlin Bicêtre, 94270
France
Le Kremlin Bicêtre, 94270
France
Phone
Undisclosed
Website
Email Address
Overview
We are on a mission to accelerate drug discovery in oncology; Orakl Oncology partners with the oncology industry to meet the challenge of personalized medicine.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 11/12/2026: Mount Thor venture capital transaction
Next: 11/12/2026: Planky venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








